Increased plasma GLP-1 levels due to DGAT1 inhibition in humans and animals models leads to delayed gastric emptying, which might lead to vomiting and diarrhea in humans [8,24].Thus, understanding and exploring the chylomicron neutral lipid balance could help in generating better tolerable inhibitors targeting the gut metabolism to treat hyperlipidemia and obesity. Here, DGAT1 is linked to obesity due to melanocortin 4 receptor deficiency.